MedPath

Outcomes of intravitreal aflibercept (Eylea) treatment for treatment-naive contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed intravitreal ranibizumab in the first eye

Not Applicable
Conditions
eovascular age-related macular degeneration
Registration Number
JPRN-UMIN000033786
Lead Sponsor
Seoul National University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
21
Inclusion Criteria

Not provided

Exclusion Criteria

1) patients with neovascularized maculopathies other than AMD, 2) patients with a history of prior photocoagulation, intravitreal anti-VEGF injection, photodynamic therapy, intravitreal or sub-tenon steroid injection, vitrectomy surgery, or intravitreal gas injection, 3) patients with diabetic retinopathy or retinal vein occlusion, and 4) patients with coexisting epiretinal membranes or vitreomacular traction syndrome.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath